SCHEMBL6489984

SCHEMBL6489984

N#Cc1cccc(C(=O)N2CCN(c3ccc(NC(=O)C4=C(c5ccc(C(F)(F)F)cc5)CCCC4)cc3)CC2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 4/20 0.55
EPHX2 P34913 3/20 0.47
HPGDS O60760 1/20 0.46
CETP P11597 1/20 0.45
MAPT P10636 1/20 0.44
PRKAA2 P54646 1/20 0.44
SLC2A1 P11166 1/20 0.43
USP2 O75604 2/20 0.43
CYP1A2 P05177 2/20 0.43
CYP3A4 P08684 2/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
TSHR P16473 1/20 0.43
RHOA P61586 1/20 0.43
MAPKAPK2 P49137 1/20 0.42
KMT2A Q03164 1/20 0.41
KDM4E B2RXH2 1/20 0.41
POLB P06746 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6488692 0.85 SLC2A1 (0.52) CETPMAPTPRKAA2SLC2A1MAPKAPK2
SCHEMBL6490282 0.79 AR (0.45) CETPSLC2A1CYP3A4CYP2C9MAPKAPK2
SCHEMBL6496056 0.78 MAPKAPK2 (0.66) MAPTMAPKAPK2HTT
SCHEMBL11889729 0.77 NAMPT (0.68) NAMPTMAPTUSP2KMT2AKDM4E
SCHEMBL6496929 0.76 MAPT (0.57) NAMPTMAPTUSP2CYP2C19TSHR
SCHEMBL6490755 0.75 CA1 (0.51) CETPMAPTSLC2A1MAPKAPK2KDM4E
SCHEMBL6490805 0.75 HIF1A (0.64) MAPTPRKAA2USP2TSHRKMT2A
SCHEMBL6501892 0.75 TRPV1 (0.59) NAMPTMAPTMAPKAPK2KMT2AKDM4E
SCHEMBL6501481 0.74 CA1 (0.52) CETPMAPTMAPKAPK2KDM4EPOLB
SCHEMBL6680389 0.74 MAPKAPK2 (0.46) NAMPTMAPTSLC2A1USP2MAPKAPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed
EP-1472226-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-03 EP disclosed
WO-2003045921-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 NAMPT 2426/4885EPHX2 864/4885HPGDS 2302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.